Diversify and Conquer: The Vaccine Escapism of Plasmodium falciparum

Abstract

Over the last century, a great deal of effort and resources have been poured into the development of vaccines to protect against malaria, particularly targeting the most widely spread and deadly species of the human-infecting parasites: Plasmodium falciparum. Many of the known proteins the parasite uses to invade human cells have been tested as vaccine candidates. However, precisely because of the importance and immune visibility of these proteins, they tend to be very diverse, and in many cases redundant, which limits their efficacy in vaccine development. With the advent of genomics and constantly improving sequencing technologies, an increasingly clear picture is emerging of the vast genomic diversity of parasites from different geographic areas. This diversity is distributed throughout the genome and includes most of the vaccine candidates tested so far, playing an important role in the low efficacy achieved. Genomics is a powerful tool to search for genes that comply with the most desirable attributes of vaccine targets, allowing us to evaluate function, immunogenicity and also diversity in the worldwide parasite populations. Even predicting how this diversity might evolve and spread in the future becomes possible, and can inform novel vaccine efforts.

Momordica balsamina: phytochemistry and pharmacological potential of a gifted species

“…In fact, drug options are scarce and highly challenged by the emergence of resistant strains (Madhav and Hoda 2021). The same is observed for insecticides used to eliminate the vector Anopheles (Minetti et al 2020), and the available vaccines showed a low efficacy as stated in recently reviewed literature (Pance 2020).…”

The Stem Cell Revolution Revealing Protozoan Parasites’ Secrets and Paving the Way towards Vaccine Development

“…Human malaria is caused by 5 species of Plasmodium parasites of which P. falciparum is the most common and deadly while P. vivax and P. ovale form hypnozoites or dormant hepatic forms that cause recurrences of the disease and are difficult to clear. Though a vaccine (RTS,s/AS01) has recently been licensed to be deployed among African children [22], it has shown an efficacy of 30-50% so far, which is attributed to the immense genetic variability of worldwide populations of parasites [23]. The drugs currently used are losing efficacy due to increasing resistance of par- The ethical issues of embryonic stem cells have been avoided with the reprogramming of terminally differentiated cells back into pluripotency to generate iPS cells [13].…”

Future vaccines in pregnancy

“…Furthermore, there is a need to develop vaccines against the separate parasites with P. falciparum responsible for the majority of infections in Sub Sahara and P. vivax in South East Asia. The complexity of the genetic makeup of the parasites is also contributing to the delay in vaccination production, with the P. falciparum genome made of 5300 genes alone with demonstrable geographic diversity ( 28 ).…”